Are you Dr. Swan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
825 S 8th St
Ste 250
Minneapolis, MN 55404Phone+1 612-347-6450
Summary
- Dr. Suzanne Swan, MD is a nephrologist in Minneapolis, Minnesota. She is currently licensed to practice medicine in Minnesota, California, and Colorado.
Education & Training
Indiana University School of MedicineResidency, Internal Medicine, 1992 - 1993
Oregon Health & Science University (OHSU Health)Fellowship, Nephrology, 1988 - 1990
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 1986 - 1988
Texas Tech University Health Sciences Center at LubbockInternship, Internal Medicine, 1985 - 1986
Northeast Ohio Medical UniversityClass of 1985
Certifications & Licensure
OR State Medical License 1988 - Present
AR State Medical License 2023 - 2026
CA State Medical License 2024 - 2026
IL State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
CO State Medical License 2024 - 2025
MN State Medical License 1993 - 2025- American Board of Internal Medicine Internal Medicine
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 1999
Clinical Trials
- Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers Start of enrollment: 2008 Dec 01
- Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C Start of enrollment: 2009 Jul 01
Publications & Presentations
PubMed
- 8 citationsPharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic HaemodialysisBruce K. Birmingham, Suzanne K. Swan, Tom A. Puchalski, Pat Mitchell, Connie T. Azumaya
Clinical Drug Investigation. 2013-03-14 - 6 citationsEffect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonistJohn W. Bauman, Joyce M Antal, Laurel M. Adams, Brendan M. Johnson, Sharon C. Murray
Investigational New Drugs. 2012-04-01 - 2 citationsPharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects.Zhaoyang Li, Tenhoor C, Thomas Marbury, Suzanne K. Swan, Zhu Y
International Journal of Clinical Pharmacology and Therapeutics. 2011-09-01
Press Mentions
EmVenio Research Adds Principal Investigators to Research TeamAugust 3rd, 2023
Professional Memberships
- Fellow
